Navigation Links
Penn researchers use honeybee venom toxin to develop a new tool for studying hypertension
Date:9/17/2008

PHILADELPHIA - Researchers at the University of Pennsylvania School of Medicine have modified a honeybee venom toxin so that it can be used as a tool to study the inner workings of ion channels that control heart rate and the recycling of salt in kidneys. In general, ion channels selectively allow the passage of small ions such as sodium, potassium, or calcium into and out of the cell.

The study, published in the Proceedings of the National Academy of Sciences, is from the laboratory of Zhe Lu, M.D, Ph.D., Professor of Physiology and a Howard Hughes Medical Institute Investigator, who looked at the action of a natural bee toxin on inward-rectifier potassium channels, Kir channels for short, to identify new approaches to treat cardiovascular disease.

The honeybee venom toxin, called tertiapin, or TPN, stops the flow of potassium ions across cell membranes by plugging up the opening of Kir channels on the outside of cells. Kir channels in kidneys are potential new targets for treating hypertension. "The clue comes from patients with genetic defects in these channels who lose a lot of sodium because it cannot be effectively reabsorbed and thus have low blood pressure," notes Lu. "An inhibitor specifically against these kidney channels will allow this idea to be tested."

Developing a specific inhibitor for one type of Kir channel has been challenging because the target site is very similar among different types of Kir channels. For example, while TPN inhibits Kir type 1 channels in kidney cells, it also inhibits other types of Kir channels in heart cells. After more than a decade, Lu and his colleagues succeeded in bioengineering a TPN that selectively inhibits Kir channels important for salt recycling in kidneys.

By introducing two mutations into TPN, they engineered a variant, called TPNLQ, which stems the flow of potassium ions in renal Kir type 1 channels at low concentrations, and with a 250-fold sensitivity over six other types of Kir channels.

The development of TPNLQ demonstrates that a highly specific inhibitor of potassium channels can be engineered. TPNLQ can now be used as a tool to prove the concept, in animal studies, that reducing salt reabsorption by plugging up renal Kir type 1 potassium channels is a potential new way to treat hypertension.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Johns Hopkins researchers suppress hunger hormone
2. Penn researchers identify natural tumor suppressor
3. Two U.S. Researchers Win Prestigious International Science Award
4. Researchers receive grant to study ways of preventing heart disease
5. Yerkes researchers create animal model of chronic stress
6. Surgical technique halts cell loss, Parkinsons researchers find
7. Millions face undiagnosed heart risk say researchers after mass screening
8. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
9. Heart attack patients who stop statin risk death, say McGill researchers
10. UTMB researchers test new vaccine to fight multiple influenza strains
11. New method to overcome multiple drug resistant diseases developed by Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... The California State University Institute for Palliative Care ... or interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: ... San Diego on Sept. 28 and 29, 2017, on the campus of California State ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that ... Chairman of the Management Committee when IFN was originally formed in 2002 where he ... and development of the business plan. He became the first paid employee of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head ... division on February 12th. Ms. Esparza qualified into this prestigious status after ... held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... jointly issued a letter to withdraw previous guidance issued by the ... identity. The guidance issued in May 2016 by the Obama Administration came in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... to develop and market advanced products and therapies for ... and Dental sectors of healthcare, today announced its record ... December 31, 2016. Full Year 2016 Highlights ... increase over full year 2015 revenue ...
(Date:2/23/2017)... On Wednesday, February 22, 2017, US markets saw ... sectors finished the trading sessions in green, four closed in ... indices were also mixed at the close of yesterday,s session. ... by 0.09%; the Dow Jones Industrial Average edged 0.16% higher, ... 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks at the ...
(Date:2/23/2017)... 2017 Tillotts Pharma is strengthening ... Berlin office was opened in January 2017 ... portfolio includes Entocort ® for the treatment of ... ulcerative colitis, and VistaPrep ® for bowel preparation ... pharmaceutical company focused on the treatment of gastrointestinal (GI) ...
Breaking Medicine Technology: